To shorten the duration of intervention and thereby reducing the risk of prolonged or secondary infections, we treated mice directly before and during the viral infection with anti-IL-17A (Figure 4A) or IL-1Ra (Figure 5A). The gene discussed is IL17A; the disease is infection.